ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

Browse by...

Deposit

Highlights

More informations

Title		ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
Authors		Bone, Henry G Cosman, Felicia Miller, Paul D Williams, Gregory C Hattersley, Gary Hu, Ming-yi Fitzpatrick, Lorraine A Mitlak, Bruce Papapoulos, Socrates Rizzoli, René Dore, Robin K Bilezikian, John P Saag, Kenneth G show all authors [1 - 13]
Published in		Journal of Clinical Endocrinology and Metabolism. 2018, vol. 103, no. 8, p. 2949-2957
Identifiers		DOI: 10.1210/jc.2018-00163
Full text		Article (Published version) (1 MB) - Limited access to UNIGE Other version: https://academic.oup.com/jcem/article/103/8/2949/5001732
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research group		Génétique des ostéoporoses (544)
Citation (ISO format)		BONE, Henry G et al. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. In: Journal of Clinical Endocrinology and Metabolism, 2018, vol. 103, n° 8, p. 2949-2957. https://archive-ouverte.unige.ch/unige:111093